Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPTAVIR for Residual HIV in Suppressed Patients
NCT00951743Phase 2Unknown
- Sponsor
- Rapid Labs
- Start
- Jul 2009
- Primary completion
- May 2010
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Adaptavir Treatment with Placebo (2 arms). Primary endpoints: Safety and toxicity of mDAPTA at 24 weeks and Proportion of participants achieving PBMC viral culture negative status at 24 weeks. Status: unknown.
02
Drugs
DAPTA
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00951743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00951743.